Immunotherapy in Lung Cancer

August 4, 2015

Paul A. Bunn, Jr., MD, distinguished professor, Division of Medical Oncology, University of Colorado, James Dudley Chair in Lung Cancer Research, Lung Cancer: Giant of Cancer Care, discusses immunotherapy in lung cancer.

Bunn describes how it is possible to get tumor responses by inhibiting the proteins within cancer cells. These tumor responses can last for an extended period of time and potentially increase survival. Unfortunately, many patients do not benefit, and it is not known as to why.

PD-L1 is somewhat predictive as a biomarker, but a mutation would be much more beneficial, in order to ensure the success of the drug, according to Bunn.

Paul A. Bunn, Jr., MD, distinguished professor, Division of Medical Oncology, University of Colorado, James Dudley Chair in Lung Cancer Research, Lung Cancer: Giant of Cancer Care, discusses immunotherapy in lung cancer.